Bone Tissue Engineering: Current Strategies and Techniques—Part II: Cell Types

Szpalski, Caroline; Barbaro, Marissa; Sagebin, Fabio; Warren, Stephen M.

doi:10.1089/ten.teb.2011.0440

Cited by 86 publications

(75 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, a composite material made of medicalgrade polycaprolactone-tricalcium phosphate (mPCL-TCP) scaffolds (combined with recombinant human BMP-7) has been demonstrated to completely bridge a critical-sized (3 cm) tibial defect in a sheep model (102). 5) BSM with living cells Mesenchymal stem cells (103)(104)(105), bone marrow stromal cells (106)(107), periosteal cells (108)(109), osteoblasts (110) and embryonic (111) as well as adult stem cells (112) have been used in bone tissue engineering (22,101,(113)(114)(115)(116). These cells can generate new tissue alone or can be used in combination with scaffold matrices.…”

Section: Bone Substitute Materials (Bsm)mentioning

confidence: 99%

Bone Regeneration Based on Tissue Engineering Conceptions — A 21st Century Perspective

et al. 2013

View full text Add to dashboard Cite

The role of Bone Tissue Engineering in the field of Regenerative Medicine has been the topic of substantial research over the past two decades. Technological advances have improved orthopaedic implants and surgical techniques for bone reconstruction. However, improvements in surgical techniques to reconstruct bone have been limited by the paucity of autologous materials available and donor site morbidity. Recent advances in the development of biomaterials have provided attractive alternatives to bone grafting expanding the surgical options for restoring the form and function of injured bone. Specifically, novel bioactive (second generation) biomaterials have been developed that are characterised by controlled action and reaction to the host tissue environment, whilst exhibiting controlled chemical breakdown and resorption with an ultimate replacement by regenerating tissue. Future generations of biomaterials (third generation) are designed to be not only osteoconductive but also osteoinductive, i.e. to stimulate regeneration of host tissues by combining tissue engineering and in situ tissue regeneration methods with a focus on novel applications. These techniques will lead to novel possibilities for tissue regeneration and repair. At present, tissue engineered constructs that may find future use as bone grafts for complex skeletal defects, whether from post-traumatic, degenerative, neoplastic or congenital/developmental "origin" require osseous reconstruction to ensure structural and functional integrity. Engineering functional bone using combinations of cells, scaffolds and bioactive factors is a promising strategy and a particular feature for future development in the area of hybrid materials which are able to exhibit suitable biomimetic and mechanical properties. This review will discuss the state of the art in this field and what we can expect from future generations of bone regeneration concepts.

show abstract

Section: Bone Substitute Materials (Bsm)mentioning

confidence: 99%

Bone Regeneration Based on Tissue Engineering Conceptions — A 21st Century Perspective

et al. 2013

View full text Add to dashboard Cite

show abstract

“…3 Mesenchymal stem cells (MSCs) have the ability to differentiate along various lineages of mesenchymal origin, including chondrocyte, osteoblast, and adipocyte lineages, depending upon the biological environment. Moreover, MSCs can be obtained from multiple adult tissues, such as bone marrow, trabecular bone, articular cartilage, muscle, and adipose.…”

Section: Introductionmentioning

confidence: 99%

Antioxidative fullerol promotes osteogenesis of human adipose-derived stem cells

Yang¹,

Li²,

Wan³

et al. 2014

IJN

View full text Add to dashboard Cite

Antioxidants were implicated as potential reagents to enhance osteogenesis, and nano-fullerenes have been demonstrated to have a great antioxidative capacity by both in vitro and in vivo experiments. In this study, we assessed the impact of a polyhydroxylated fullerene, fullerol, on the osteogenic differentiation of human adipose-derived stem cells (ADSCs). Fullerol was not toxic against human ADSCs at concentrations up to 10 μM. At a concentration of 1 μM, fullerol reduced cellular reactive oxygen species after a 5-day incubation either in the presence or in the absence of osteogenic media. Pretreatment of fullerol for 7 days increased the osteogenic potential of human ADSCs. Furthermore, when incubated together with osteogenic medium, fullerol promoted osteogenic differentiation in a dose-dependent manner. Finally, fullerol proved to promote expression of FoxO1, a major functional isoform of forkhead box O transcription factors that defend against reactive oxygen species in bone. Although further clarification of related mechanisms is required, the findings may help further development of a novel approach for bone repair, using combined treatment of nano-fullerol with ADSCs.

show abstract

“…Of these compounds, miR148b has been shown to induce de novo osteogenesis in bone marrow-derived MSC and ASC and has been demonstrated to enhance progenitor osteogenesis and bone repair both in vitro and in vivo [79,[81][82][83] . Several miRNAs such as miR-146a, miR-9, miR-29a and miR-140 play a role in the regulation of chondrogenesis [84][85][86][87][88][89] . In addition, different drug delivery systems can be incorporated into "bioinks" and be deposited in regions that require controlled release of cell-signaling molecules [90] .…”

Section: Towards Mimicking the Heterogeneity And Anisotropymentioning

confidence: 99%

Bioprinting of osteochondral tissues: A perspective on current gaps and future trends

Datta

Dhawan

et al. 2024

IJB

View full text Add to dashboard Cite

Abstract:Osteochondral tissue regeneration has remained a critical challenge in orthopaedic surgery, especially due to complications of arthritic degeneration arising out of mechanical dislocations of joints. The common gold standard of autografting has several limitations in presenting tissue engineering strategies to solve the unmet clinical need. However, due to the complexity of joint anatomy, and tissue heterogeneity at the interface, the conventional tissue engineering strategies have certain limitations. The advent of bioprinting has now provided new opportunities for osteochondral tissue engineering. Bioprinting can uniquely mimic the heterogeneous cellular composition and anisotropic extra-cellular matrix (ECM) organization, while allowing for targeted gene delivery to achieve heterotypic differentiation. In this perspective, we discuss the current advances made towards bioprinting of composite osteochondral tissues and present an account of challenges-in terms of tissue integration, long-term survival, and mechanical strength at the time of implantation-required to be addressed for effective clinical translation of bioprinted tissues. Finally, we highlight some of the future trends related to osteochondral bioprinting with the hope of in-clinical translation. Keywords: bioprinting; osteochondral injuries; zonal anisotropy; bioink; tissue engineering

show abstract

Bone Tissue Engineering: Current Strategies and Techniques—Part II: Cell Types

Cited by 86 publications

References 97 publications

Bone Regeneration Based on Tissue Engineering Conceptions — A 21st Century Perspective

Bone Regeneration Based on Tissue Engineering Conceptions — A 21st Century Perspective

Antioxidative fullerol promotes osteogenesis of human adipose-derived stem cells

Bioprinting of osteochondral tissues: A perspective on current gaps and future trends

Contact Info

Product

Resources

About